Literature DB >> 16570345

Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.

Judith Y M N Engwegen1, Helgi H Helgason, Annemieke Cats, Nathan Harris, Johannes M G Bonfrer, Jan H M Schellens, Jos H Beijnen.   

Abstract

AIM: To detect the new serum biomarkers for colorectal cancer (CRC) by serum protein profiling with surface-enhanced laser desorption ionisation--time of flight mass spectrometry (SELDI-TOF MS).
METHODS: Two independent serum sample sets were analysed separately with the ProteinChip technology (set A: 40 CRC+49 healthy controls; set B: 37 CRC+31 healthy controls), using chips with a weak cation exchange moiety and buffer pH 5. Discriminative power of differentially expressed proteins was assessed with a classification tree algorithm. Sensitivities and specificities of the generated classification trees were obtained by blindly applying data from set A to the generated trees from set B and vice versa. CRC serum protein profiles were also compared with those from breast, ovarian, prostate, and non-small cell lung cancer.
RESULTS: Mass-to-charge ratios (m/z) 3.1x10(3), 3.3x10(3), 4.5x10(3), 6.6x10(3) and 28x10(3) were used as classifiers in the best-performing classification trees. Tree sensitivities and specificities were between 65% and 90%. Most of these discriminative m/z values were also different in the other tumour types investigated. M/z 3.3x10(3), main classifier in most trees, was a doubly charged form of the 6.6x10(3)-Da protein. The latter was identified as apolipoprotein C-I. M/z 3.1x10(3) was identified as an N-terminal fragment of albumin, and m/z 28x10(3) as apolipoprotein A-I.
CONCLUSION: SELDI-TOF MS followed by classification tree pattern analysis is a suitable technique for finding new serum markers for CRC. Biomarkers can be identified and reproducibly detected in independent sample sets with high sensitivities and specificities. Although not specific for CRC, these biomarkers have a potential role in disease and treatment monitoring.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570345      PMCID: PMC4124285          DOI: 10.3748/wjg.v12.i10.1536

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

Review 1.  Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?

Authors:  M J Duffy
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

2.  Proteolysis in colorectal cancer.

Authors:  E A Garbett; M W Reed; N J Brown
Journal:  Mol Pathol       Date:  1999-06

3.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

Authors:  R C Bast; P Ravdin; D F Hayes; S Bates; H Fritsche; J M Jessup; N Kemeny; G Y Locker; R G Mennel; M R Somerfield
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

4.  A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.

Authors:  P D Greenberg; L Bertario; R Gnauck; O Kronborg; J D Hardcastle; M S Epstein; D Sadowski; R Sudduth; G R Zuckerman; D C Rockey
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

5.  Use of proteomic patterns in serum to identify ovarian cancer.

Authors:  Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

6.  Expression of apolipoprotein A1 in colonic adenocarcinoma.

Authors:  Masayoshi Tachibana; Yasuo Ohkura; Yasuhito Kobayashi; Hirohiko Sakamoto; Yoichi Tanaka; Junko Watanabe; Katsumi Amikura; Yoji Nishimura; Kiwamu Akagi
Journal:  Anticancer Res       Date:  2003 Sep-Oct       Impact factor: 2.480

7.  [Identification of colorectal cancer using proteomic patterns in serum].

Authors:  Guang Zhao; Chun-Fang Gao; Guo-Ying Song; Dong-Hui Li; Xiu-Li Wang
Journal:  Ai Zheng       Date:  2004-06

8.  ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke.

Authors:  Laure Allard; Pierre Lescuyer; Jennifer Burgess; Kit-Yi Leung; Malcolm Ward; Nadia Walter; Pierre R Burkhard; Garry Corthals; Denis F Hochstrasser; Jean-Charles Sanchez
Journal:  Proteomics       Date:  2004-08       Impact factor: 3.984

9.  An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics.

Authors:  Jie-Kai Yu; Yi-Ding Chen; Shu Zheng
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

10.  Assessment of the value of preoperative serum levels of CA 242 and CEA in the staging and postoperative survival of colorectal adenocarcinoma patients.

Authors:  S B Kim; L C Fernandes; S S Saad; D Matos
Journal:  Int J Biol Markers       Date:  2003 Jul-Sep       Impact factor: 3.248

View more
  53 in total

Review 1.  Screening for colorectal cancer: established and emerging modalities.

Authors:  Nikhil Pawa; Tan Arulampalam; John D Norton
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-01       Impact factor: 46.802

2.  New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.

Authors:  Thomas Göbel; Sonja Vorderwülbecke; Katarzyna Hauck; Holger Fey; Dieter Häussinger; Andreas Erhardt
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

3.  Apolipoprotein A1 and C-terminal fragment of α-1 antichymotrypsin are candidate plasma biomarkers associated with acute renal allograft rejection.

Authors:  Mary E Ziegler; Tingchao Chen; James F LeBlanc; Xuelian Wei; David W Gjertson; Ker-Chau Li; Mazdak A Khalighi; Charles R Lassman; Jeffrey L Veale; H Albin Gritsch; Elaine F Reed
Journal:  Transplantation       Date:  2011-08-27       Impact factor: 4.939

4.  Search for breast cancer biomarkers in fractionated serum samples by protein profiling with SELDI-TOF MS.

Authors:  Annemieke W J Opstal-van Winden; Jos H Beijnen; Arnoud Loof; Waander L van Heerde; Roel Vermeulen; Petra H M Peeters; Carla H van Gils
Journal:  J Clin Lab Anal       Date:  2012-01       Impact factor: 2.352

Review 5.  Novel translational strategies in colorectal cancer research.

Authors:  Ignacio Gil-Bazo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 6.  Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears.

Authors:  M E de Noo; R A E M Tollenaar; A M Deelder; L H Bouwman
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

7.  The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Kaori Yamamoto-Ishikawa; Hiroyoshi Suzuki; Masahiko Nezu; Naoto Kamiya; Takashi Imamoto; Akira Komiya; Kazuyuki Sogawa; Takeshi Tomonaga; Fumio Nomura; Tomohiko Ichikawa
Journal:  Asian J Androl       Date:  2009-02-02       Impact factor: 3.285

8.  Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy.

Authors:  P Kelly; V Appleyard; K Murray; F Paulin; D Lamont; L Baker; S Suttie; D Exon; A Thompson
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

Review 9.  Innovations, challenges and future prospects of oncoproteomics.

Authors:  Kewal K Jain
Journal:  Mol Oncol       Date:  2008-05-28       Impact factor: 6.603

10.  Plasma protein profiles differ between women diagnosed with cervical intraepithelial neoplasia (cin) 1 and 3.

Authors:  Chandrika J Piyathilake; Denise K Oelschlager; Sreelatha Meleth; Edward E Partridge; William E Grizzle
Journal:  Cancer Inform       Date:  2007-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.